Table 3.
Cox Regression Univariate Model Results for Flow Markersa
| Flow Marker | No. With Abnormal Expression | HR (95% CI) | P Value |
|---|---|---|---|
| CD13/HLA-DR | 21 | 2.85 (1.36-5.95) | .005 |
| CD7 | 4 | 3.49 (1.04-11.71) | .044 |
| CD2 | 3 | 0.72 (0.10-5.31) | .75 |
| CD13/CD16 | 6 | 1.16 (0.28-4.90) | .84 |
| CD45 | 24 | 1.07 (0.50-2.30) | .87 |
| CD56 | 4 | 0.49 (0.07-3.58) | .48 |
| SSC | 7 | 1.16 (0.35-3.85) | .81 |
| CD13/HLA-DR, CD13/CD16, or CD7 (vs not any) | 26 | 2.46 (1.19-5.12) | .016 |
CI, confidence interval; HR, hazard ratio; MN, myeloid neoplasia.
aEach row in this table reflects a separate univariate Cox regression model, where the results associated with the marker are presented for risk of MN or death. CD13/CD16, CD2, CD7, CD56, and SSC should be interpreted with caution because of the small number of patients (<10) with abnormal expression of those single markers.